Stock comparison

BSXvsMCK

Boston Scientific CorpvsMcKesson Corp. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.

BSX

Boston Scientific Corp

$64.87

-29.93%

Health Care$91.9BNYSE

MCK

McKesson Corp

$836.1

+3.67%

Health Care$108.3BNYSE

60-day price, rebased to 100

BSX -30.83% · MCK -1.23%

Round-by-round

BSX 2·MCK 4

EdgeMCK

Valuation upside

-27.90% vs +529.30% to DCF fair value

EdgeMCK

Balance-sheet strength

Altman Z 3.90 vs 6.07

EdgeBSX

Fundamental quality

Piotroski 9.00 vs 3.00 (of 9)

EdgeBSX

Growth + margins

Rule-of-40 36.80 vs 1.50

EdgeMCK

60-day momentum

-30.83% vs -1.23% price return

EdgeMCK

Market-cap liquidity

$91.9B vs $108.3B

Verdict

Across6categories,MCKtakes the edge with4wins to2. Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.

Backtest a strategy onBSXorMCK

Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.